MENU

RGNX Stock REGENXBIO (RGNX, $7.77) Moving Average Convergence Divergence (MACD) Histogram turned positive on January 3, 2025

A.I.dvisor
at Tickeron.com
Loading...
RGNX - REGENXBIO
MACD signal
Bullish Trend
Odds of UP Trend
Tickeron
MACD signal
Price: $7.77
Daily change: -$0.09 (-1.15%)
Daily volume: 1.3M
Capitalization: $385M
Industry: Biotechnology
This is a Bullish indicator signaling RGNX's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 49 similar cases where RGNX's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:

RGNX's RSI Indicator recovers from oversold territory

The RSI Indicator for RGNX moved out of oversold territory on December 20, 2024. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In of the 34 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for RGNX just turned positive on January 03, 2025. Looking at past instances where RGNX's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RGNX advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 13, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on RGNX as a result. In of 107 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGNX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for RGNX entered a downward trend on January 14, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.211) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (87.786). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.852). RGNX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (4.177) is also within normal values, averaging (263.573).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. RGNX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of gene therapy treatments

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
9804 Medical Center Drive
Phone
+1 240 552-8181
Employees
344
Web
https://www.regenxbio.com